Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Keeping Track Of CRLs: US FDA Again Faults Bausch + Lomb Manufacturing

Aug 11 2017

• By Bridget Silverman

Keeping Track Feature image

Related Content

Keeping Track: Approval Elusive For Biosimilar Neulasta; Valeant Gets A Nod And A No From FDA; Submissions From Amgen, Puma, Bristol

Jul 22 2016

Keeping Track: Tremfya Clears FDA; Dextenza Amendment Is Too Late; Emicizumab, Abemaciclib Filed

Jul 17 2017

Keeping Track: US FDA Expands Indications For Roche Tecentriq, Lucentis, Approves Second Infliximab Biosimilar

Apr 24 2017

Cempra Gets Easier Path To CRL Response, But Who Will Fund The Study?

Aug 09 2017

Ocular Analyzes Particulates Root Cause After Whiffing With Steel Blade

Aug 09 2017

Keeping Track: Lower Doses Of Narcan, Linzess Approved; US FDA Receives Actemra, Ryanodex, Dextenza Submissions

Jan 28 2017

Keeping Track: Merck's Winning Week; Novel Agents Submitted By GSK, Melinta, Portola

Oct 30 2016

Related Companies

Bausch Health Companies Inc.

Ocular Therapeutix, Inc.

Aerie Pharmaceuticals, Inc.

Eagle Pharmaceuticals, Inc.

Seelos Therapeutics, Inc.

Melinta Therapeutics, Inc.

Melinta Therapeutics, Inc.

Bausch Health Companies Inc.

Nicox S.A.

Seelos Therapeutics, Inc.

Ligand Pharmaceuticals, Inc.

Tris Pharma, Inc.

Additional Topics

US States Complete Response Letters Regulation Research & Development BioPharmaceutical

More from Complete Response Letters

More from Product Reviews

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window